Abstract: Dibenzopyran derivatives which possess antihypoxia activity are 7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyranyloxyaminopropanols having the formula: ##STR1## Where X is oxygen or dialkyl in which each alkyl group contains one to seven carbons (C.sub.1 -C.sub.7); R is hydrogen or alkyl containing one to seven carbons (C.sub.1 -C.sub.7); and A is --NR.sub.1 R.sub.2 where R.sub.1 and R.sub.2 may independently be hydrogen, C.sub.1 -C.sub.7 alkyl, C.sub.3 -C.sub.7 cycloalkyl, phenyl, C.sub.7 -C.sub.10 phenylalkyl, C.sub.7 -C.sub.10 phenoxyalkyl, C.sub.2 -C.sub.6 alkanol, 6-oxo-6H-dibenzo[b,d]pyran-3-yl, 2-hydroxy-3-(7,8,9,10-tetrahydro-6-oxo-6H-dibenzo[b,d]pyranyl-3-oxy)-propy l; or A is a heterocyclic ring of structure: ##STR2## where n=2 or 3; or A is a substituted heterocyclic ring of structure: ##STR3## where Y and Z may be independently hydrogen or methyl and B represents a single bond, methylene, ethylene, propylene, CH-phenyl, CHCH.sub.2 -phenyl, oxygen, sulfur, or N--R.sub.4 where R.sub.4 is hydrogen, C.sub.

Abstract: The invention provides various medical compositions for use in treating or preventing certain of the side effects of diabetes or galactosemia. The active ingredients are selected from a series of novel aldose reductase inhibitory spiro-linked pyrrolidine-2,5-diones of the general formula: ##STR1## or a pharmaceutically acceptable salt, or a non-toxic, biodegradable precursor thereof. Processes for the production of these compounds are also provided. A particular compound suitable for use as an active ingredient is spiro[pyrrolidine-3,9'-xanthene]-2,5-dione.

Abstract: Compounds corresponding to the general formula: ##STR1## in which X and Y identical or different, represent a hydrogen or a halogen atom, a lower alkyl, a lower alkoxy or a trifluormethyl group,A represents a methylene group, a direct bond or an imino--NR.sub.3 -- group in which R.sub.3 is a hydrogen atom or a lower alkyl or lower alkanoyl groupR.sub.1 and R.sub.2 identical or different, each represents a hydrogen atom or a lower alkyl group, or together with the nitrogen atom to which they are attached they form a pyrrolidino, piperidino or methyl-4 piperazine group, andn represents an integer from 1 to 3, in their racemic or optical isomeric forms, as well as their salts of addition with a therapeutically compatible mineral or organic acid.These compounds are useful as antidepressants.

Abstract: The present invention relates to new 6-substituted 6H-dibenzo [b,d]pyran derivatives, to a process for their preparation and pharmaceutical and veterinary compositions containing them.

Abstract: An improved immunoassay for detecting cannabinoids is described. This immunoassay is characterized by utilizing, as reagents, antibody, .sup.125 I-radiolabeled antigen, an unlabeled antigen and an anion exchange resin for separation of labeled and unlabeled antigen. The iodinated tetrahydrocannabinol moiety is stabilized by the addition of small quantities of antioxidants such as butylated hydroxy toluene.

Abstract: (-)-6a,10a-Trans-1-hydroxy-3-n-pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro dibenzo[b,d]pyran or any of its related pyrans in which the n-pentyl group is replaced by hydrogen or C.sub.1 -C.sub.10 alkyl is isolated from a crude synthetic mixture by a process which comprises esterifying the mixture to form perfluorinated alkanoic acid esters, removing low-boiling and non-volatile components, passing the mixture through a first gas chromatographic column with a packing whose liquid phase consists of a slightly polar phenyl-substituted silicone oil and recovering a fraction rich in the desired component, passing the recovered fraction through a second gas chromatographic column with a packing whose liquid phase consists of a non-phenyl-substituted silicone oil and recovering a fraction rich in the desired component, hydrolyzing the fraction recovered from the second stage, and recovering the desired product from the hydrolysis mixture.